Showing results (151-160 of 234) with videos related to
Sort By:
Pageof 24
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.Blood|February 7, 2012
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in JapanTakashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, et al.British Journal of Haematology|January 12, 2026
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphomaKunhwa Kim, Rahul Shah, Amy Ayers, et al.British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.Pageof 24